25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

BLRX (Biolinerx) Stock Analysis
Buy, Hold or Sell?

Let's analyze Biolinerx together

I guess you are interested in BioLineRx Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Biolinerx’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Biolinerx’s Price Targets

I'm going to help you getting a better view of BioLineRx Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about BioLineRx Ltd

I send you an email if I find something interesting about BioLineRx Ltd.

1. Quick Overview

1.1. Quick analysis of Biolinerx (30 sec.)










1.2. What can you expect buying and holding a share of Biolinerx? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.01
Expected worth in 1 year
$-0.16
How sure are you?
15.0%

+ What do you gain per year?

Total Gains per Share
$-0.17
Return On Investment
-3.8%

For what price can you sell your share?

Current Price per Share
$4.53
Expected price per share
$3.61 - $7.808
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Biolinerx (5 min.)




Live pricePrice per Share (EOD)
$4.53
Intrinsic Value Per Share
$-11.79 - $12.40
Total Value Per Share
$-11.78 - $12.41

2.2. Growth of Biolinerx (5 min.)




Is Biolinerx growing?

Current yearPrevious yearGrowGrow %
How rich?$20.8m$15.1m-$915.5k-6.4%

How much money is Biolinerx making?

Current yearPrevious yearGrowGrow %
Making money-$849.5k-$12.2m$11.4m1,346.4%
Net Profit Margin468.7%-74.9%--

How much money comes from the company's main activities?

2.3. Financial Health of Biolinerx (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#511 / 884

Most Revenue
#347 / 884

Most Profit
#230 / 884
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Biolinerx?

Welcome investor! Biolinerx's management wants to use your money to grow the business. In return you get a share of Biolinerx.

First you should know what it really means to hold a share of Biolinerx. And how you can make/lose money.

Speculation

The Price per Share of Biolinerx is $4.53. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Biolinerx.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Biolinerx, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.01. Based on the TTM, the Book Value Change Per Share is $-0.04 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.11 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Biolinerx.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.000.1%-0.03-0.6%-0.19-4.2%-0.15-3.4%-0.20-4.4%-0.69-15.2%
Usd Book Value Change Per Share-0.16-3.5%-0.04-0.9%-0.11-2.5%-0.11-2.4%-0.12-2.7%-0.36-8.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.16-3.5%-0.04-0.9%-0.11-2.5%-0.11-2.4%-0.12-2.7%-0.36-8.0%
Usd Price Per Share2.96-1.07-1.53-1.17-1.60-1.39-
Price to Earnings Ratio322.24-85.64--8.56-25.29-13.88-6.77-
Price-to-Total Gains Ratio-18.59--33.28--95.88--45.60--25.46--14.03-
Price to Book Ratio316.77-81.58-7.00-29.85-18.50-9.35-
Price-to-Total Gains Ratio-18.59--33.28--95.88--45.60--25.46--14.03-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share4.53
Number of shares220
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.04-0.12
Usd Total Gains Per Share-0.04-0.12
Gains per Quarter (220 shares)-9.40-26.55
Gains per Year (220 shares)-37.61-106.22
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-38-480-106-116
20-75-860-212-222
30-113-1240-319-328
40-150-1620-425-434
50-188-2000-531-540
60-226-2380-637-646
70-263-2760-744-752
80-301-3140-850-858
90-338-3520-956-964
100-376-3900-1062-1070

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share2.02.00.050.0%2.010.00.016.7%2.018.00.010.0%3.037.00.07.5%4.058.00.06.5%
Book Value Change Per Share1.03.00.025.0%1.011.00.08.3%4.016.00.020.0%6.034.00.015.0%12.047.03.019.4%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.062.00.0%
Total Gains per Share1.03.00.025.0%1.011.00.08.3%4.016.00.020.0%6.034.00.015.0%12.047.03.019.4%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of BioLineRx Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.159-0.043-73%-0.114-28%-0.110-31%-0.121-24%-0.364+129%
Book Value Per Share--0.0090.115-92%0.230-96%0.442-98%0.881-99%4.528-100%
Current Ratio--2.2751.790+27%1.853+23%2.902-22%3.580-36%6.188-63%
Debt To Asset Ratio--0.5210.699-26%0.734-29%0.582-11%0.467+11%0.319+63%
Debt To Equity Ratio--1.0862.949-63%2.902-63%2.111-49%1.464-26%0.847+28%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--6585853890.4001664938077.150+296%91994636.488+7059%610144018.571+979%408486509.625+1512%223562001.810+2846%
Eps--0.002-0.026+1237%-0.191+8404%-0.152+6715%-0.199+8759%-0.691+30170%
Ev To Sales Ratio--6456.7201614.995+300%4.029+160152%1078.007+499%1078.007+499%1078.007+499%
Free Cash Flow Per Share---0.001-0.094+7961%-0.111+9501%-0.115+9780%-0.151+12930%-0.572+49182%
Free Cash Flow To Equity Per Share--0.003-0.025+914%-0.060+2056%-0.039+1359%0.025-88%-0.194+6428%
Gross Profit Margin--1.000-1.429+243%3.535-72%1.177-15%1.128-11%1.097-9%
Intrinsic Value_10Y_max--12.397----------
Intrinsic Value_10Y_min---11.792----------
Intrinsic Value_1Y_max---0.213----------
Intrinsic Value_1Y_min---2.113----------
Intrinsic Value_3Y_max--0.470----------
Intrinsic Value_3Y_min---5.580----------
Intrinsic Value_5Y_max--2.489----------
Intrinsic Value_5Y_min---8.178----------
Market Cap16856130.000-39105%6608501890.4001678475577.150+294%101218386.488+6429%609207518.571+985%397075109.625+1564%202354626.810+3166%
Net Profit Margin--20.1064.687+329%-0.749+104%1.313+1432%0.788+2453%0.394+5005%
Operating Margin----0.0670%-0.7650%-0.2770%-0.1660%-0.0830%
Operating Ratio--10.5104.012+162%1.294+712%1.768+494%1.061+890%0.531+1881%
Pb Ratio484.790+35%316.77281.582+288%6.998+4427%29.851+961%18.503+1612%9.346+3289%
Pe Ratio493.158+35%322.24085.641+276%-8.564+103%25.287+1174%13.884+2221%6.775+4657%
Price Per Share4.530+35%2.9601.070+177%1.526+94%1.172+153%1.602+85%1.393+113%
Price To Free Cash Flow Ratio-975.848-53%-637.640-160.057-75%-0.275-100%-54.001-92%-33.774-95%-17.062-97%
Price To Total Gains Ratio-28.451-53%-18.591-33.277+79%-95.876+416%-45.604+145%-25.457+37%-14.035-25%
Quick Ratio--1.3402.008-33%2.966-55%4.585-71%5.885-77%11.084-88%
Return On Assets--0.118-0.017+114%-0.212+280%-0.114+197%-0.111+194%-0.105+189%
Return On Equity--0.246-0.160+165%-0.801+426%-0.379+254%-0.298+221%-0.212+186%
Total Gains Per Share---0.159-0.043-73%-0.114-28%-0.110-31%-0.121-24%-0.364+129%
Usd Book Value--20862000.00014202250.000+47%15117750.000+38%26610583.333-22%36816800.000-43%40488925.000-48%
Usd Book Value Change Per Share---0.159-0.043-73%-0.114-28%-0.110-31%-0.121-24%-0.364+129%
Usd Book Value Per Share--0.0090.115-92%0.230-96%0.442-98%0.881-99%4.528-100%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--6585853890.4001664938077.150+296%91994636.488+7059%610144018.571+979%408486509.625+1512%223562001.810+2846%
Usd Eps--0.002-0.026+1237%-0.191+8404%-0.152+6715%-0.199+8759%-0.691+30170%
Usd Free Cash Flow---2591000.000-8094250.000+212%-7225250.000+179%-7531250.000+191%-6805850.000+163%-6315575.000+144%
Usd Free Cash Flow Per Share---0.001-0.094+7961%-0.111+9501%-0.115+9780%-0.151+12930%-0.572+49182%
Usd Free Cash Flow To Equity Per Share--0.003-0.025+914%-0.060+2056%-0.039+1359%0.025-88%-0.194+6428%
Usd Market Cap16856130.000-39105%6608501890.4001678475577.150+294%101218386.488+6429%609207518.571+985%397075109.625+1564%202354626.810+3166%
Usd Price Per Share4.530+35%2.9601.070+177%1.526+94%1.172+153%1.602+85%1.393+113%
Usd Profit--5127000.000-849500.000+117%-12287000.000+340%-7081500.000+238%-6959450.000+236%-6113125.000+219%
Usd Revenue--255000.0005585000.000-95%2913750.000-91%2832916.667-91%1699750.000-85%849875.000-70%
Usd Total Gains Per Share---0.159-0.043-73%-0.114-28%-0.110-31%-0.121-24%-0.364+129%
 EOD+2 -6MRQTTM+24 -12YOY+23 -133Y+21 -155Y+18 -1810Y+22 -14

3.3 Fundamental Score

Let's check the fundamental score of BioLineRx Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15493.158
Price to Book Ratio (EOD)Between0-1484.790
Net Profit Margin (MRQ)Greater than020.106
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.340
Current Ratio (MRQ)Greater than12.275
Debt to Asset Ratio (MRQ)Less than10.521
Debt to Equity Ratio (MRQ)Less than11.086
Return on Equity (MRQ)Greater than0.150.246
Return on Assets (MRQ)Greater than0.050.118
Total6/10 (60.0%)

3.4 Technical Score

Let's check the technical score of BioLineRx Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5052.077
Ma 20Greater thanMa 504.791
Ma 50Greater thanMa 1003.958
Ma 100Greater thanMa 2003.581
OpenGreater thanClose4.570
Total4/5 (80.0%)

4. In-depth Analysis

4.1 About BioLineRx Ltd

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Fundamental data was last updated by Penke on 2025-06-19 01:13:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Biolinerx earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Biolinerx to theΒ Biotechnology industry mean.
  • A Net Profit Margin of 2,010.6%Β means thatΒ $20.11 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of BioLineRx Ltd:

  • The MRQ is 2,010.6%. The company is making a huge profit. +2
  • The TTM is 468.7%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ2,010.6%TTM468.7%+1,541.9%
TTM468.7%YOY-74.9%+543.5%
TTM468.7%5Y78.8%+389.9%
5Y78.8%10Y39.4%+39.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2,010.6%-92.7%+2,103.3%
TTM468.7%-141.4%+610.1%
YOY-74.9%-186.1%+111.2%
3Y131.3%-248.3%+379.6%
5Y78.8%-338.6%+417.4%
10Y39.4%-488.9%+528.3%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Biolinerx is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Biolinerx to theΒ Biotechnology industry mean.
  • 11.8% Return on Assets means thatΒ Biolinerx generatedΒ $0.12 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of BioLineRx Ltd:

  • The MRQ is 11.8%. Using its assets, the company is efficient in making profit. +1
  • The TTM is -1.7%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ11.8%TTM-1.7%+13.5%
TTM-1.7%YOY-21.2%+19.5%
TTM-1.7%5Y-11.1%+9.4%
5Y-11.1%10Y-10.5%-0.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ11.8%-11.5%+23.3%
TTM-1.7%-11.6%+9.9%
YOY-21.2%-11.4%-9.8%
3Y-11.4%-11.8%+0.4%
5Y-11.1%-12.1%+1.0%
10Y-10.5%-13.8%+3.3%
4.3.1.3. Return on Equity

Shows how efficient Biolinerx is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Biolinerx to theΒ Biotechnology industry mean.
  • 24.6% Return on Equity means Biolinerx generated $0.25Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of BioLineRx Ltd:

  • The MRQ is 24.6%. Using its investors money, the company is efficient in making profit. +1
  • The TTM is -16.0%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ24.6%TTM-16.0%+40.6%
TTM-16.0%YOY-80.1%+64.1%
TTM-16.0%5Y-29.8%+13.8%
5Y-29.8%10Y-21.2%-8.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ24.6%-13.6%+38.2%
TTM-16.0%-14.9%-1.1%
YOY-80.1%-14.4%-65.7%
3Y-37.9%-17.0%-20.9%
5Y-29.8%-17.9%-11.9%
10Y-21.2%-20.1%-1.1%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of BioLineRx Ltd.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Biolinerx is operatingΒ .

  • Measures how much profit Biolinerx makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Biolinerx to theΒ Biotechnology industry mean.
  • An Operating Margin of 0.0%Β means the company generated $0.00 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of BioLineRx Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-6.7%+6.7%
TTM-6.7%YOY-76.5%+69.8%
TTM-6.7%5Y-16.6%+10.0%
5Y-16.6%10Y-8.3%-8.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--229.2%+229.2%
TTM-6.7%-250.3%+243.6%
YOY-76.5%-205.1%+128.6%
3Y-27.7%-220.2%+192.5%
5Y-16.6%-342.6%+326.0%
10Y-8.3%-475.5%+467.2%
4.3.2.2. Operating Ratio

Measures how efficient Biolinerx is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 10.51 means that the operating costs are $10.51 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of BioLineRx Ltd:

  • The MRQ is 10.510. The company is inefficient in keeping operating costs low. -1
  • The TTM is 4.012. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ10.510TTM4.012+6.498
TTM4.012YOY1.294+2.718
TTM4.0125Y1.061+2.951
5Y1.06110Y0.531+0.531
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ10.5102.110+8.400
TTM4.0122.704+1.308
YOY1.2943.063-1.769
3Y1.7683.576-1.808
5Y1.0614.713-3.652
10Y0.5316.512-5.981
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of BioLineRx Ltd.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Biolinerx is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 2.27Β means the company has $2.27 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of BioLineRx Ltd:

  • The MRQ is 2.275. The company is able to pay all its short-term debts. +1
  • The TTM is 1.790. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.275TTM1.790+0.485
TTM1.790YOY1.853-0.063
TTM1.7905Y3.580-1.790
5Y3.58010Y6.188-2.609
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.2753.661-1.386
TTM1.7903.786-1.996
YOY1.8534.121-2.268
3Y2.9024.680-1.778
5Y3.5805.765-2.185
10Y6.1886.150+0.038
4.4.3.2. Quick Ratio

Measures if Biolinerx is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Biolinerx to theΒ Biotechnology industry mean.
  • A Quick Ratio of 1.34Β means the company can pay off $1.34 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of BioLineRx Ltd:

  • The MRQ is 1.340. The company is able to pay all its short-term debts with the most liquid assets. +1
  • The TTM is 2.008. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.340TTM2.008-0.668
TTM2.008YOY2.966-0.958
TTM2.0085Y5.885-3.877
5Y5.88510Y11.084-5.199
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.3402.826-1.486
TTM2.0083.128-1.120
YOY2.9663.782-0.816
3Y4.5854.304+0.281
5Y5.8855.703+0.182
10Y11.0846.454+4.630
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of BioLineRx Ltd.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of BiolinerxΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Biolinerx to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.52Β means that Biolinerx assets areΒ financed with 52.1% credit (debt) and the remaining percentage (100% - 52.1%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of BioLineRx Ltd:

  • The MRQ is 0.521. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.699. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.521TTM0.699-0.179
TTM0.699YOY0.734-0.034
TTM0.6995Y0.467+0.232
5Y0.46710Y0.319+0.148
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5210.324+0.197
TTM0.6990.347+0.352
YOY0.7340.327+0.407
3Y0.5820.339+0.243
5Y0.4670.349+0.118
10Y0.3190.382-0.063
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Biolinerx is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Biolinerx to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 108.6% means that company has $1.09 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of BioLineRx Ltd:

  • The MRQ is 1.086. The company is able to pay all its debts with equity. +1
  • The TTM is 2.949. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ1.086TTM2.949-1.864
TTM2.949YOY2.902+0.047
TTM2.9495Y1.464+1.485
5Y1.46410Y0.847+0.617
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0860.383+0.703
TTM2.9490.436+2.513
YOY2.9020.410+2.492
3Y2.1110.446+1.665
5Y1.4640.460+1.004
10Y0.8470.509+0.338
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Biolinerx generates.

  • Above 15 is considered overpriced butΒ always compareΒ Biolinerx to theΒ Biotechnology industry mean.
  • A PE ratio of 322.24 means the investor is paying $322.24Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of BioLineRx Ltd:

  • The EOD is 493.158. Based on the earnings, the company is expensive. -2
  • The MRQ is 322.240. Based on the earnings, the company is expensive. -2
  • The TTM is 85.641. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD493.158MRQ322.240+170.918
MRQ322.240TTM85.641+236.599
TTM85.641YOY-8.564+94.205
TTM85.6415Y13.884+71.756
5Y13.88410Y6.775+7.110
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD493.158-2.197+495.355
MRQ322.240-2.027+324.267
TTM85.641-2.527+88.168
YOY-8.564-3.733-4.831
3Y25.287-3.717+29.004
5Y13.884-6.036+19.920
10Y6.775-6.649+13.424
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of BioLineRx Ltd:

  • The EOD is -975.848. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -637.640. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -160.057. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-975.848MRQ-637.640-338.208
MRQ-637.640TTM-160.057-477.583
TTM-160.057YOY-0.275-159.782
TTM-160.0575Y-33.774-126.283
5Y-33.77410Y-17.062-16.712
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-975.848-3.007-972.841
MRQ-637.640-2.704-634.936
TTM-160.057-3.627-156.430
YOY-0.275-4.334+4.059
3Y-54.001-5.070-48.931
5Y-33.774-8.532-25.242
10Y-17.062-9.305-7.757
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Biolinerx is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 316.77 means the investor is paying $316.77Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of BioLineRx Ltd:

  • The EOD is 484.790. Based on the equity, the company is expensive. -2
  • The MRQ is 316.772. Based on the equity, the company is expensive. -2
  • The TTM is 81.582. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD484.790MRQ316.772+168.018
MRQ316.772TTM81.582+235.190
TTM81.582YOY6.998+74.584
TTM81.5825Y18.503+63.079
5Y18.50310Y9.346+9.157
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD484.7901.921+482.869
MRQ316.7721.843+314.929
TTM81.5822.113+79.469
YOY6.9982.467+4.531
3Y29.8512.541+27.310
5Y18.5033.666+14.837
10Y9.3464.311+5.035
4.6.2. Total Gains per Share

2.4. Latest News of BioLineRx Ltd

Does BioLineRx Ltd still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from BioLineRx Ltd to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-06-17
13:34
BioLineRx stock maintains buy rating at H.C. Wainwright on cancer dataRead

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of BioLineRx Ltd.

4.8.1. Institutions holding BioLineRx Ltd

Institutions are holding 0.222% of the shares of BioLineRx Ltd.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-12-31Geneos Wealth Management Inc0.0032048003006.6667
2025-03-31Morgan Stanley - Brokerage Accounts0.06030224422440
2025-03-31BNP Paribas Arbitrage, SA0.0470174817480
2025-03-31Rhumbline Advisers0.04110153015300
2025-03-31JPMorgan Chase & Co0.010103753750
2025-03-31Goss Wealth Management LLC0.002901071070
2025-03-31Group One Trading, LP0.0021079790
2025-03-31SBI Securities Co Ltd0.00010220
2025-03-31Bank of America Corp0.00010220
2025-03-31CapTrust Financial Advisors000-502-100
2024-12-31Creative Planning Inc000-12982-100
2024-12-31Envestnet Asset Management Inc000-239186-100
2024-12-31Susquehanna International Group, LLP000-18032-100
2024-12-31Wells Fargo & Co000-35035-100
2024-12-31Cutter & CO Brokerage, Inc.000-16667-100
2024-12-31Atria Wealth Solutions, Inc.000-94133-100
2024-12-31Rathbone Brothers PLC000-39820-100
2025-03-31Watts Gwilliam and Company, LLC000-850-100
2024-12-31Wealth Enhancement Advisory Services, LLC000-10500-100
2025-03-31Values First Advisors Inc000-4161-100
Total 0.1669010887-465481-4,275.6%

4.9.2. Funds holding BioLineRx Ltd

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31Fidelity Nasdaq Composite Index0.0404099900
Total 0.0404099900.0%
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets43,510
Total Liabilities22,648
Total Stockholder Equity20,862
 As reported
Total Liabilities 22,648
Total Stockholder Equity+ 20,862
Total Assets = 43,510

Assets

Total Assets43,510
Total Current Assets31,917
Long-term Assets11,593
Total Current Assets
Cash And Cash Equivalents 9,036
Short-term Investments 17,333
Net Receivables 1,469
Inventory 3,315
Total Current Assets  (as reported)31,917
Total Current Assets  (calculated)31,153
+/- 764
Long-term Assets
Property Plant Equipment 1,162
Long-term Assets  (as reported)11,593
Long-term Assets  (calculated)1,162
+/- 10,431

Liabilities & Shareholders' Equity

Total Current Liabilities14,030
Long-term Liabilities8,618
Total Stockholder Equity20,862
Total Current Liabilities
Short Long Term Debt 4,684
Accounts payable 4,693
Other Current Liabilities 2,462
Total Current Liabilities  (as reported)14,030
Total Current Liabilities  (calculated)11,839
+/- 2,191
Long-term Liabilities
Long term Debt 7,633
Capital Lease Obligations Min Short Term Debt1,425
Long-term Liabilities  (as reported)8,618
Long-term Liabilities  (calculated)9,058
+/- 440
Total Stockholder Equity
Total Stockholder Equity (as reported)20,862
Total Stockholder Equity (calculated)0
+/- 20,862
Other
Capital Stock62,570
Common Stock Shares Outstanding 2,232,602
Net Debt 3,281
Net Invested Capital 33,179
Net Working Capital 17,887
Property Plant and Equipment Gross 1,162



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-31
> Total Assets 
159,167
0
0
0
43,570
41,022
37,713
33,043
29,338
39,313
33,343
28,165
24,307
30,658
24,956
22,142
19,948
38,977
35,034
30,958
36,166
59,873
58,355
55,031
51,302
48,941
45,680
42,277
38,939
41,118
63,048
66,127
60,965
56,075
52,213
46,400
56,233
67,594
61,958
57,225
53,567
47,171
52,989
46,039
47,290
83,599
91,329
86,905
81,391
74,773
67,838
81,673
76,384
68,646
58,936
52,855
63,925
51,600
64,596
52,742
38,906
43,510
43,51038,90652,74264,59651,60063,92552,85558,93668,64676,38481,67367,83874,77381,39186,90591,32983,59947,29046,03952,98947,17153,56757,22561,95867,59456,23346,40052,21356,07560,96566,12763,04841,11838,93942,27745,68048,94151,30255,03158,35559,87336,16630,95835,03438,97719,94822,14224,95630,65824,30728,16533,34339,31329,33833,04337,71341,02243,570000159,167
   > Total Current Assets 
147,047
0
0
0
0
38,383
35,087
30,680
27,156
37,148
31,368
26,266
22,178
28,976
23,334
20,553
18,773
37,826
33,894
29,897
35,114
58,430
55,692
51,885
48,183
45,869
42,694
39,414
36,101
31,648
53,663
55,847
50,376
45,544
42,797
37,104
31,978
41,649
36,207
31,702
28,210
22,140
28,169
21,423
22,880
59,352
67,072
62,846
57,404
50,941
44,103
57,942
52,001
44,327
34,692
28,805
47,183
35,691
49,110
37,849
27,104
31,917
31,91727,10437,84949,11035,69147,18328,80534,69244,32752,00157,94244,10350,94157,40462,84667,07259,35222,88021,42328,16922,14028,21031,70236,20741,64931,97837,10442,79745,54450,37655,84753,66331,64836,10139,41442,69445,86948,18351,88555,69258,43035,11429,89733,89437,82618,77320,55323,33428,97622,17826,26631,36837,14827,15630,68035,08738,3830000147,047
       Cash And Cash Equivalents 
105,890
0
0
0
31,490
15,630
11,062
9,051
8,687
25,236
16,309
13,429
18,292
12,765
13,770
12,041
8,869
9,123
8,437
4,715
5,783
8,075
9,404
5,320
5,544
4,584
3,877
4,014
2,469
2,201
6,946
6,712
5,110
7,810
5,789
4,703
3,404
4,384
4,972
4,885
5,297
5,072
5,523
6,552
16,831
16,047
17,484
14,077
12,990
11,446
14,000
13,105
10,587
9,066
10,104
7,727
4,255
5,990
9,623
8,836
10,436
9,036
9,03610,4368,8369,6235,9904,2557,72710,1049,06610,58713,10514,00011,44612,99014,07717,48416,04716,8316,5525,5235,0725,2974,8854,9724,3843,4044,7035,7897,8105,1106,7126,9462,2012,4694,0143,8774,5845,5445,3209,4048,0755,7834,7158,4379,1238,86912,04113,77012,76518,29213,42916,30925,2368,6879,05111,06215,63031,490000105,890
       Short-term Investments 
0
0
0
0
7,901
20,915
0
20,980
17,284
11,097
14,332
12
3,067
15,274
9,111
8,040
9,288
28,212
24,760
24,945
28,854
49,418
45,385
45,387
42,119
40,423
37,945
34,894
33,154
28,167
45,616
48,295
44,373
36,388
35,339
30,300
26,747
36,224
30,256
25,255
22,192
16,109
21,779
14,275
5,756
42,036
48,083
48,128
44,145
39,144
29,146
44,157
40,495
34,221
22,711
18,241
38,739
22,183
30,437
20,337
9,126
17,333
17,3339,12620,33730,43722,18338,73918,24122,71134,22140,49544,15729,14639,14444,14548,12848,08342,0365,75614,27521,77916,10922,19225,25530,25636,22426,74730,30035,33936,38844,37348,29545,61628,16733,15434,89437,94540,42342,11945,38745,38549,41828,85424,94524,76028,2129,2888,0409,11115,2743,0671214,33211,09717,28420,980020,9157,9010000
       Net Receivables 
40,063
0
0
0
0
1,806
1,910
564
1,005
499
451
461
603
706
299
245
226
226
414
60
641
641
653
992
396
396
548
303
580
580
541
558
586
782
438
1,339
1,339
528
528
1,285
613
682
441
327
190
190
668
192
190
240
240
143
721
302
128
315
708
2,832
3,835
3,961
3,863
1,469
1,4693,8633,9613,8352,8327083151283027211432402401901926681901903274416826131,2855285281,3391,339438782586558541580580303548396396992653641641604142262262452997066034614514991,0055641,9101,806000040,063
       Other Current Assets 
1,094
0
0
0
13
66
22,115
85
181
11,413
276
12,377
216
461
608
453
258
492
697
236
221
296
250
186
229
466
324
203
255
700
560
282
307
564
1,231
1,266
488
583
451
277
108
277
426
269
152
1,079
837
449
127
161
717
537
198
738
1,749
1,170
1,528
1,797
1,581
1,171
534
0
05341,1711,5811,7971,5281,1701,7497381985377171611274498371,0791522694262771082774515834881,2661,23156430728256070025520332446622918625029622123669749225845360846121612,37727611,4131818522,11566130001,094
   > Long-term Assets 
0
0
0
0
0
2,639
2,626
2,363
2,182
2,165
1,974
1,898
2,129
1,682
1,623
1,589
1,175
1,151
1,141
1,061
1,052
1,443
2,663
3,146
3,119
3,072
2,986
2,863
2,838
9,470
9,385
10,280
10,589
10,531
9,416
9,296
24,255
25,945
25,751
25,523
25,357
25,031
24,820
24,616
24,410
24,247
24,257
24,059
23,987
23,832
23,735
23,731
24,383
24,319
24,244
24,050
16,742
15,909
15,486
14,893
11,802
11,593
11,59311,80214,89315,48615,90916,74224,05024,24424,31924,38323,73123,73523,83223,98724,05924,25724,24724,41024,61624,82025,03125,35725,52325,75125,94524,2559,2969,41610,53110,58910,2809,3859,4702,8382,8632,9863,0723,1193,1462,6631,4431,0521,0611,1411,1511,1751,5891,6231,6822,1291,8981,9742,1652,1822,3632,6262,63900000
       Property Plant Equipment 
4,175
0
0
0
1,271
1,242
1,237
1,088
1,106
1,069
932
868
849
807
787
751
710
687
680
632
720
1,111
2,489
2,962
2,909
2,859
2,770
2,654
2,605
2,540
2,463
2,365
2,505
2,432
2,318
2,197
2,227
3,940
3,763
3,558
3,466
3,263
3,070
2,885
2,696
2,540
2,551
2,354
2,283
2,128
2,031
2,015
2,498
2,358
2,231
2,023
1,888
1,719
1,796
1,647
1,353
1,162
1,1621,3531,6471,7961,7191,8882,0232,2312,3582,4982,0152,0312,1282,2832,3542,5512,5402,6962,8853,0703,2633,4663,5583,7633,9402,2272,1972,3182,4322,5052,3652,4632,5402,6052,6542,7702,8592,9092,9622,4891,1117206326806877107517878078498689321,0691,1061,0881,2371,2421,2710004,175
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
21,682
21,682
21,694
21,939
21,939
21,991
0
0
0
0
0
0
0
000000021,99121,93921,93921,69421,68221,6820000000000000000000000000000000000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,000
1,000
1,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000001,0001,0001,0000000000000000000000000000000000
       Intangible Assets 
3,042
0
0
0
381
372
350
315
301
303
279
269
285
289
255
255
252
245
248
227
117
116
117
128
152
157
162
155
181
6,875
6,869
6,855
7,023
7,039
7,035
7,033
21,972
21,950
21,928
21,906
21,891
21,768
21,750
21,731
21,714
21,707
21,706
21,705
21,704
21,704
22
22
21,885
22
22
22,027
14,854
14,190
13,690
13,246
10,449
0
010,44913,24613,69014,19014,85422,027222221,885222221,70421,70421,70521,70621,70721,71421,73121,75021,76821,89121,90621,92821,95021,9727,0337,0357,0397,0236,8556,8696,8751811551621571521281171161172272482452522552552892852692793033013153503723810003,042
       Long-term Assets Other 
0
0
0
0
0
1,025
1,039
960
775
793
764
761
995
586
580
582
213
219
213
202
214
216
57
56
58
56
54
54
52
55
53
60
61
60
63
66
56
55
60
59
25,357
25,031
21,750
21,731
21,398
0
21,706
21,705
0
21,704
0
0
0
0
0
0
0
0
13,690
0
0
0
00013,6900000000021,704021,70521,706021,39821,73121,75025,03125,3575960555666636061605355525454565856572162142022132192135825805869957617647937759601,0391,02500000
> Total Liabilities 
41,230
0
0
0
6,384
6,485
6,941
6,681
6,806
11,194
9,367
9,901
9,336
10,399
7,663
8,063
8,265
6,747
5,749
4,093
4,400
5,685
6,539
4,360
3,692
2,939
3,116
3,668
3,912
5,402
5,618
7,102
8,084
7,053
6,027
5,815
14,912
21,706
20,176
18,027
20,187
18,663
23,759
21,231
25,260
18,952
17,436
16,004
13,304
11,360
11,270
26,149
25,543
29,532
37,882
39,721
50,702
38,540
50,615
44,237
25,445
22,648
22,64825,44544,23750,61538,54050,70239,72137,88229,53225,54326,14911,27011,36013,30416,00417,43618,95225,26021,23123,75918,66320,18718,02720,17621,70614,9125,8156,0277,0538,0847,1025,6185,4023,9123,6683,1162,9393,6924,3606,5395,6854,4004,0935,7496,7478,2658,0637,66310,3999,3369,9019,36711,1946,8066,6816,9416,4856,38400041,230
   > Total Current Liabilities 
41,230
0
0
0
6,254
6,376
6,852
6,622
6,755
7,404
6,470
6,716
6,427
7,452
5,196
4,333
2,999
3,190
2,754
2,615
2,902
4,145
4,152
3,590
3,140
2,559
2,805
3,367
3,661
5,174
5,414
5,526
6,722
6,180
5,338
4,925
6,751
8,135
8,559
10,091
11,968
11,766
11,723
10,476
10,641
10,216
9,917
10,313
9,719
9,098
9,632
8,133
10,679
12,041
12,446
14,725
30,852
31,373
30,516
24,962
15,406
14,030
14,03015,40624,96230,51631,37330,85214,72512,44612,04110,6798,1339,6329,0989,71910,3139,91710,21610,64110,47611,72311,76611,96810,0918,5598,1356,7514,9255,3386,1806,7225,5265,4145,1743,6613,3672,8052,5593,1403,5904,1524,1452,9022,6152,7543,1902,9994,3335,1967,4526,4276,7166,4707,4046,7556,6226,8526,3766,25400041,230
       Short-term Debt 
0
0
0
0
0
88
90
82
81
83
65
44
292
15
0
0
0
0
0
0
0
0
0
93
93
93
93
93
93
93
93
93
93
93
93
93
895
3,022
3,067
3,815
2,894
2,974
3,067
3,169
3,283
3,360
3,528
3,744
2,925
2,050
1,162
953
1,969
2,937
3,453
3,604
3,673
4,147
11,156
10,339
5,001
0
05,00110,33911,1564,1473,6733,6043,4532,9371,9699531,1622,0502,9253,7443,5283,3603,2833,1693,0672,9742,8943,8153,0673,02289593939393939393939393939393000000000152924465838182908800000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
93
0
0
0
93
320
296
93
93
93
93
93
895
1,636
2,395
3,164
2,692
2,777
2,867
2,969
3,092
3,220
3,354
3,575
2,757
1,903
1,013
802
1,542
2,558
3,078
3,078
3,145
3,680
10,656
9,822
4,479
4,684
4,6844,4799,82210,6563,6803,1453,0783,0782,5581,5428021,0131,9032,7573,5753,3543,2203,0922,9692,8672,7772,6923,1642,3951,63689593939393932963209300093000000000000000000000000
       Accounts payable 
6,452
0
0
0
1,751
886
1,259
1,482
2,962
3,281
2,805
2,967
3,288
5,987
4,135
3,521
2,289
1,970
1,864
1,521
1,654
2,614
2,959
2,349
1,910
1,465
1,732
2,274
2,590
3,450
4,262
4,349
5,516
4,941
4,128
3,804
4,493
4,817
4,565
5,303
7,794
7,489
7,396
5,933
5,918
5,756
5,318
5,441
5,567
5,784
7,338
5,829
6,966
7,136
6,733
8,438
10,869
8,256
6,266
4,633
5,583
4,693
4,6935,5834,6336,2668,25610,8698,4386,7337,1366,9665,8297,3385,7845,5675,4415,3185,7565,9185,9337,3967,4897,7945,3034,5654,8174,4933,8044,1284,9415,5164,3494,2623,4502,5902,2741,7321,4651,9102,3492,9592,6141,6541,5211,8641,9702,2893,5214,1355,9873,2882,9672,8053,2812,9621,4821,2598861,7510006,452
       Other Current Liabilities 
34,778
0
0
0
4,416
5,402
5,504
5,058
2,492
4,041
3,600
3,705
2,419
1,466
1,061
812
764
1,220
891
1,094
1,252
1,531
1,193
1,148
1,137
1,001
980
1,000
978
1,631
1,059
1,084
1,113
1,146
1,117
1,028
1,363
296
927
973
1,280
1,303
1,260
1,374
1,440
1,100
1,071
1,128
1,227
1,264
1,132
1,351
1,744
1,968
2,260
2,683
16,310
-5,033
13,094
7,735
4,822
2,462
2,4624,8227,73513,094-5,03316,3102,6832,2601,9681,7441,3511,1321,2641,2271,1281,0711,1001,4401,3741,2601,3031,2809739272961,3631,0281,1171,1461,1131,0841,0591,6319781,0009801,0011,1371,1481,1931,5311,2521,0948911,2207648121,0611,4662,4193,7053,6004,0412,4925,0585,5045,4024,41600034,778
   > Long-term Liabilities 
0
0
0
0
0
109
88
59
51
3,790
2,897
3,185
2,909
2,947
2,467
3,730
5,266
3,557
2,995
1,478
1,498
1,540
2,387
770
552
380
311
301
251
228
204
1,576
1,362
873
689
890
8,161
13,571
11,617
7,936
8,219
6,897
12,036
10,755
14,619
8,736
7,519
5,691
3,585
2,262
1,638
18,016
14,864
17,491
25,436
24,996
19,850
7,167
20,099
19,275
10,039
8,618
8,61810,03919,27520,0997,16719,85024,99625,43617,49114,86418,0161,6382,2623,5855,6917,5198,73614,61910,75512,0366,8978,2197,93611,61713,5718,1618906898731,3621,5762042282513013113805527702,3871,5401,4981,4782,9953,5575,2663,7302,4672,9472,9093,1852,8973,79051598810900000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7,838
8,358
7,679
7,073
7,561
6,715
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000006,7157,5617,0737,6798,3587,838000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
8
0
0
0
22
3,765
2,880
3,208
2,917
2,958
2,480
3,746
5,270
3,567
3,006
1,480
1,494
1,540
2,387
404
208
60
15
29
1
1
1
1,396
1,205
740
580
804
323
5,213
3,938
863
658
182
6,077
5,600
10,218
5,247
4,812
4,013
1,859
604
186
8,156
0
0
15,352
0
0
0
0
0
0
0
000000015,352008,1561866041,8594,0134,8125,24710,2185,6006,0771826588633,9385,2133238045807401,2051,3961112915602084042,3871,5401,4941,4803,0063,5675,2703,7462,4802,9582,9173,2082,8803,7652200080000
> Total Stockholder Equity
117,937
0
0
0
37,186
34,537
30,772
26,362
22,532
28,119
23,975
18,264
14,971
20,258
17,293
14,079
11,683
32,230
29,285
26,865
31,766
54,188
51,816
50,671
47,610
46,002
42,564
38,609
35,027
35,716
57,430
59,025
52,881
49,022
46,186
40,585
41,321
45,888
41,782
39,198
33,380
28,508
29,230
24,808
22,030
64,647
73,893
70,901
68,087
63,413
56,568
55,524
50,841
39,114
21,054
13,134
13,223
13,060
13,981
8,505
13,461
20,862
20,86213,4618,50513,98113,06013,22313,13421,05439,11450,84155,52456,56863,41368,08770,90173,89364,64722,03024,80829,23028,50833,38039,19841,78245,88841,32140,58546,18649,02252,88159,02557,43035,71635,02738,60942,56446,00247,61050,67151,81654,18831,76626,86529,28532,23011,68314,07917,29320,25814,97118,26423,97528,11922,53226,36230,77234,53737,186000117,937
   Common Stock
1,235
0
0
0
348
353
361
330
325
474
450
447
492
609
629
661
693
970
994
926
1,004
1,420
1,448
1,450
1,455
1,459
1,459
1,460
1,513
1,642
2,570
2,809
2,836
2,874
2,920
2,922
3,110
3,928
4,001
4,129
4,692
4,907
8,281
8,281
9,870
18,731
20,496
20,874
21,066
21,066
21,157
27,098
27,100
27,100
27,100
28,332
31,355
31,355
34,411
34,430
38,097
0
038,09734,43034,41131,35531,35528,33227,10027,10027,10027,09821,15721,06621,06620,87420,49618,7319,8708,2818,2814,9074,6924,1294,0013,9283,1102,9222,9202,8742,8362,8092,5701,6421,5131,4601,4591,4591,4551,4501,4481,4201,0049269949706936616296094924474504743253303613533480001,235
   Retained Earnings -394,700-399,827-396,640-390,818-391,302-390,606-376,722-360,699-342,154-329,992-324,261-317,414-309,971-305,041-300,737-295,021-288,179-277,987-265,999-261,381-254,611-247,966-238,098-234,160-228,675-222,520-216,868-210,544-205,756-199,558-192,201-184,958-180,061-175,206-170,921-166,588-162,854-159,365-155,713-154,086-149,276-140,063-143,752-153,607-146,548-145,234-137,448-129,589-125,130-118,936-106,603-101,534-103,908-96,708-94,497-101,033-94,0970000-325,323
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
250,192
259,860
261,522
262,430
265,938
267,140
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000267,140265,938262,430261,522259,860250,192000000000000000000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
442,025
0
0
0
0
128,281
131,444
120,529
110,687
122,874
125,059
106,621
118,951
135,705
137,250
142,960
146,359
168,747
171,618
160,255
167,331
193,426
195,583
195,950
196,201
197,792
197,858
198,380
199,567
205,892
231,368
239,606
240,682
242,177
243,883
244,058
250,192
259,860
261,522
262,430
265,938
267,140
271,107
271,107
279,241
321,920
335,887
338,051
339,346
339,444
339,670
338,841
338,976
339,042
339,045
345,462
355,482
355,482
352,428
354,413
359,060
0
0359,060354,413352,428355,482355,482345,462339,045339,042338,976338,841339,670339,444339,346338,051335,887321,920279,241271,107271,107267,140265,938262,430261,522259,860250,192244,058243,883242,177240,682239,606231,368205,892199,567198,380197,858197,792196,201195,950195,583193,426167,331160,255171,618168,747146,359142,960137,250135,705118,951106,621125,059122,874110,687120,529131,444128,2810000442,025



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue28,940
Cost of Revenue-9,263
Gross Profit19,67719,677
 
Operating Income (+$)
Gross Profit19,677
Operating Expense-40,085
Operating Income-20,408-20,408
 
Operating Expense (+$)
Research Development9,149
Selling General Administrative18,460
Selling And Marketing Expenses10,080
Operating Expense40,08537,689
 
Net Interest Income (+$)
Interest Income1,820
Interest Expense-9,074
Other Finance Cost-45
Net Interest Income-7,299
 
Pretax Income (+$)
Operating Income-20,408
Net Interest Income-7,299
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-9,221-31,595
EBIT - interestExpense = -9,221
-9,221
-147
Interest Expense9,074
Earnings Before Interest and Taxes (EBIT)-147-147
Earnings Before Interest and Taxes (EBITDA)3,918
 
After tax Income (+$)
Income Before Tax-9,221
Tax Provision-0
Net Income From Continuing Ops-9,221-9,221
Net Income-9,221
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses49,348
Total Other Income/Expenses Net11,1877,299
 

Technical Analysis of Biolinerx
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Biolinerx. The general trend of Biolinerx is BULLISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Biolinerx's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (14.3%) Bearish trend (-14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Biolinerx Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of BioLineRx Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 6.59 < 7.7699 < 7.808.

The bearish price targets are: 4.17 > 3.79 > 3.61.

Know someone who trades $BLRX? Share this with them.πŸ‘‡

BioLineRx Ltd Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of BioLineRx Ltd. The current mas is .

The long score for the Moving Averages is 8/14.
The longshort score for the Moving Averages is 2/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

BioLineRx Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of BioLineRx Ltd. The current macd is 0.10192267.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Biolinerx price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Biolinerx. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Biolinerx price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
BioLineRx Ltd Daily Moving Average Convergence/Divergence (MACD) ChartBioLineRx Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of BioLineRx Ltd. The current adx is 33.72.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Biolinerx shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
BioLineRx Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of BioLineRx Ltd. The current sar is 6.20238534.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
BioLineRx Ltd Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of BioLineRx Ltd. The current rsi is 52.08. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending down: The RSI is trending down. -1
BioLineRx Ltd Daily Relative Strength Index (RSI) ChartBioLineRx Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of BioLineRx Ltd. The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Biolinerx price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
BioLineRx Ltd Daily Stochastic Oscillator ChartBioLineRx Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of BioLineRx Ltd. The current cci is -40.92300917.

BioLineRx Ltd Daily Commodity Channel Index (CCI) ChartBioLineRx Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of BioLineRx Ltd. The current cmo is 0.64025682.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
BioLineRx Ltd Daily Chande Momentum Oscillator (CMO) ChartBioLineRx Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of BioLineRx Ltd. The current willr is -65.51724138.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Biolinerx is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
BioLineRx Ltd Daily Williams %R ChartBioLineRx Ltd Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of BioLineRx Ltd.

BioLineRx Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of BioLineRx Ltd. The current atr is 0.50395875.

BioLineRx Ltd Daily Average True Range (ATR) ChartBioLineRx Ltd Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of BioLineRx Ltd. The current obv is 36,826,649.

BioLineRx Ltd Daily On-Balance Volume (OBV) ChartBioLineRx Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of BioLineRx Ltd. The current mfi is 15.46.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
BioLineRx Ltd Daily Money Flow Index (MFI) ChartBioLineRx Ltd Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for BioLineRx Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-07STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-02-11RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-02-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-19CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-02-27WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-03CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-04STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-07STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-10CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-13STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-17MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-03-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-03-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-03-21CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-03-24STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-28SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-31CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-04-01STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-03STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-08STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-09RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-04-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-15CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-16STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-23WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-25DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-04-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-30STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-01STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-13STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-16STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-05-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-22STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-27MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-28STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-30STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-02RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-03SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-06-04STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-06-05BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-06-10STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-11RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2025-06-13CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-06-17WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-26STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-30STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside

6.3. Candlestick Patterns

BioLineRx Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of BioLineRx Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5052.077
Ma 20Greater thanMa 504.791
Ma 50Greater thanMa 1003.958
Ma 100Greater thanMa 2003.581
OpenGreater thanClose4.570
Total4/5 (80.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Biolinerx with someone you think should read this too:
  • Are you bullish or bearish on Biolinerx? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Biolinerx? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about BioLineRx Ltd

I send you an email if I find something interesting about BioLineRx Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about BioLineRx Ltd.

Receive notifications about BioLineRx Ltd in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.